{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:06:22Z","timestamp":1785456382184,"version":"3.56.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["82171897"],"award-info":[{"award-number":["82171897"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Plan of SHDC","award":["SHDC2020CR1029B"],"award-info":[{"award-number":["SHDC2020CR1029B"]}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["23Y11907400"],"award-info":[{"award-number":["23Y11907400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-024-04194-y","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:02:01Z","timestamp":1709301721000},"page":"3015-3023","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["How to differentiate between combined hepatocellular carcinoma-cholangiocarcinoma and intrahepatic cholangiocarcinoma with rim arterial phase hyperenhancement?"],"prefix":"10.1007","volume":"49","author":[{"given":"Changwu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengsu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"4194_CR1","unstructured":"Sempoux C, Kakar S, Kondo F et al (2019) Combined hepatocellular-cholangiocarcinoma. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. WHO classification of tumours: digestive system tumours. 5th ed. Lyon: IARC:260\u2013262"},{"key":"4194_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.humpath.2019.11.001","volume":"96","author":"A Sciarra","year":"2020","unstructured":"Sciarra A, ParK Y N, Sempoux C (2020) Updates in the diagnosis of combined hepatocellular-cholangiocarcinoma. Hum Pathol 96:48-55","journal-title":"Hum Pathol"},{"key":"4194_CR3","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s00330-021-08188-y","volume":"32","author":"CW Zhou","year":"2022","unstructured":"Zhou C W, Wang Y, Ma L et al (2022) Combined hepatocellular carcinoma-cholangiocarcinoma: MRI features correlated with tumor biomarkers and prognosis. Eur Radiol 32:78-88","journal-title":"Eur Radiol"},{"key":"4194_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00330-018-5605-x","volume":"29","author":"SK Jeon","year":"2019","unstructured":"Jeon S K, Joo I, Lee D H et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373-382","journal-title":"Eur Radiol"},{"key":"4194_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/hep.29789","volume":"68","author":"E Brunt","year":"2018","unstructured":"Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology 68:113-126","journal-title":"Hepatology"},{"key":"4194_CR6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.3348\/kjr.2020.0091","volume":"21","author":"TH Kim","year":"2020","unstructured":"Kim T H, Kim H, Joo I et al (2020) Combined Hepatocellular- Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis. Korean J Radiol 21:1115-1125","journal-title":"Korean J Radiol"},{"key":"4194_CR7","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1007\/s00330-018-5893-1","volume":"29","author":"HS Lee","year":"2019","unstructured":"Lee H S, Kim M J, An C (2019) How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?. Eur Radiol 29:2408-2416","journal-title":"Eur Radiol"},{"key":"4194_CR8","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1007\/s00261-020-02545-z","volume":"45","author":"MY Kim","year":"2020","unstructured":"Kim M Y, Joo I, Kang H J et al (2020) LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI. Abdom Radiol (NY) 45:2440-2448","journal-title":"Abdom Radiol (NY)"},{"key":"4194_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler K J, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology 289:816-830","journal-title":"Radiology"},{"key":"4194_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.crad.2019.01.016","volume":"74","author":"Y Wang","year":"2019","unstructured":"Wang Y, Yang Q, Li S et al (2019) Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population. Clin Radiol 74:e1-407","journal-title":"Clin Radiol"},{"key":"4194_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/jmri.23728","volume":"36","author":"J Hwang","year":"2012","unstructured":"Hwang J, Kim Y K, Park M J et al (2012) Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J Magn Reson Imaging 36:881-889","journal-title":"J Magn Reson Imaging"},{"key":"4194_CR12","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1007\/s00330-020-07488-z","volume":"31","author":"H Jiang","year":"2021","unstructured":"Jiang H, Song B, Qin Y et al (2021) Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 31:3638-3648","journal-title":"Eur Radiol"},{"key":"4194_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00261-013-0069-6","volume":"39","author":"AS Shetty","year":"2014","unstructured":"Shetty AS, Fowler KJ, Brunt EM, Agarwal S, Narra VR, Menias CO (2014) Combined hepatocellular-cholangiocarcinoma:what the radiologist needs to know about biphenotypic liver carcinoma. Abdom Imaging 39:310-322","journal-title":"Abdom Imaging"},{"key":"4194_CR14","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4254\/wjh.v9.i6.300","volume":"9","author":"S Gera","year":"2017","unstructured":"Gera S, Ettel M, Acosta-Gonzalez G, Xu R (2017) Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma. World J Hepatol 9:300-309","journal-title":"World J Hepatol"},{"key":"4194_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/jso.23289","volume":"107","author":"RT Groeschl","year":"2013","unstructured":"Groeschl R T, Turaga K K, Gamblin T C (2013) Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol 107:608-612","journal-title":"J Surg Oncol"},{"key":"4194_CR16","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1245\/s10434-012-2328-0","volume":"19","author":"X Yin","year":"2012","unstructured":"Yin X, Zhang BH, Qiu SJ et al (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19:2869-2876","journal-title":"Ann Surg Oncol"},{"key":"4194_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2019.10.009","volume":"72","author":"RK Kelley","year":"2020","unstructured":"Kelley R K, Bridgewater J, Gores G J et al (2020) Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol 72:353-363","journal-title":"J Hepatol"},{"key":"4194_CR18","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1007\/s00330-020-06861-2","volume":"30","author":"XL Wang","year":"2020","unstructured":"Wang XL, Wang WT, Ma XJ et al (2020) Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Eur Radiol 30:5337-5347","journal-title":"Eur Radiol"},{"key":"4194_CR19","doi-asserted-by":"publisher","first-page":"E437","DOI":"10.1111\/hepr.12335","volume":"44","author":"A Kudo","year":"2014","unstructured":"Kudo A, Matsumura S, Ban D et al (2014) Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res 44:E437-E446","journal-title":"Hepatol Res"},{"key":"4194_CR20","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1007\/s00330-022-09131-5","volume":"33","author":"YY Xiao","year":"2023","unstructured":"Xiao Y Y, Zheng X D, Zhou C W et al (2023) Combined hepatocellular carcinoma-cholangiocarcinoma with a predominant HCC component: better survival and MRI-based prediction. Eur Radiol 33:1412-1421","journal-title":"Eur Radiol"},{"key":"4194_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3348\/kjr.2015.16.1.50","volume":"16","author":"I Joo","year":"2015","unstructured":"Joo I, Kim H, Lee JM (2015) Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol 16:50-68","journal-title":"Korean J Radiol"},{"key":"4194_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jso.24381","volume":"114","author":"JR Bergquist","year":"2016","unstructured":"Bergquist JR, Ivanics T, Storlie CB et al (2016) Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: a national cohort analysis. J Surg Oncol 114:475-482","journal-title":"J Surg Oncol"},{"key":"4194_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00261-018-1727-5","volume":"44","author":"S Kim","year":"2019","unstructured":"Kim S, An C, Han K et al (2019) Gadoxetic acid enhanced magnetic resonance imaging for prediction of the postoperative prognosis of intrahepatic mass-forming cholangiocarcinoma. Abdom Radiol 44:110-121","journal-title":"Abdom Radiol"},{"key":"4194_CR24","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00261-012-9943-x","volume":"38","author":"HJ Park","year":"2013","unstructured":"Park H J, Kim Y K, Park M J et al (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793-801","journal-title":"Abdom Imaging"},{"key":"4194_CR25","doi-asserted-by":"publisher","first-page":"20180017","DOI":"10.1259\/bjr.20180017","volume":"91","author":"T Ni","year":"2018","unstructured":"Ni T, Shang X S, Wang W T et al (2018) Different MR features for differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma according to tumor size. Br J Radiol 91:20180017","journal-title":"Br J Radiol"},{"key":"4194_CR26","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/jmri.25568","volume":"46","author":"SH Park","year":"2017","unstructured":"Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267-280","journal-title":"J Magn Reson Imaging"},{"key":"4194_CR27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1148\/radiology.203.1.9122423","volume":"203","author":"JM Lacomis","year":"1997","unstructured":"Lacomis JM, Baron RL, Oliver JH, Nalesnik MA, Federle MP (1997) Cholangiocarcinoma: delayed CT contrast enhancement patterns. Radiology 203:98-104","journal-title":"Radiology"},{"key":"4194_CR28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1148\/radiol.2381041765","volume":"238","author":"Y Asayama","year":"2006","unstructured":"Asayama Y, Yoshimitsu K, Irie H et al (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150-155","journal-title":"Radiology"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04194-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-024-04194-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04194-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T17:20:02Z","timestamp":1724433602000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-024-04194-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["4194"],"URL":"https:\/\/doi.org\/10.1007\/s00261-024-04194-y","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,1]]},"assertion":[{"value":"17 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Zhongshan Hospital, Fudan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}